Although identified as a major endogenous, mechanism‐based inhibitor of tPA and uPA, to the best of our knowledge, PAI‐1 is not considered a molecular target in fibrinolytic therapy of empyema, possibly because an initial multifold excess of the exogenous plasminogen activator is employed. This evidence concerns the gene SERPINE1 and empyema.